Quick Links
> Clinical Trials Info
>Sign up for e-mail updates
>Support the Faustman Lab
>Host an event or fundraiser
>Patient information forms
> Clinical Trials Info
>Sign up for e-mail updates
>Support the Faustman Lab
>Host an event or fundraiser
>Patient information forms
Dr. Denise Faustman
Get updates on our research
Keep in touch with the Faustman Lab. Sign up for e-mail updates on the clinical trials and more.
>Sign up
Keep in touch with the Faustman Lab. Sign up for e-mail updates on the clinical trials and more.
>Sign up
>Get information on our clinical trials
For questions about the clinical trial, please e-mail us directly.
>E-mail us
For questions about the clinical trial, please e-mail us directly.
>E-mail us
Follow us
Our Phase II Trial Has Launched Read the press release
Interested in the Phase II Trial?
Please email us directly.
------------
Your donation will directly support our Phase II research.
Raised to date: $20 million
Our total need: $25.2 million.
Raised to date: $20 million
Our total need: $25.2 million.
The Faustman Lab at Massachusetts General Hospital
Denise Faustman, MD, PhD, is Director of the Immunobiology Laboratory at the Massachusetts General Hospital (MGH) and an Associate Professor of Medicine at Harvard Medical School. Her current research focuses on discovering and developing new treatments for type 1 diabetes and other autoimmune diseases, including Crohn's disease, lupus, scleroderma, rheumatoid arthritis, Sjögren's syndrome, and multiple sclerosis. She is currently leading a human clinical trial program testing the efficacy of the BCG vaccine for reversal of long-term type 1 diabetes. Positive results from the Phase I study were reported in 2012.Dr. Faustman's type 1 diabetes research has earned her notable awards such as the Oprah Achievement Award for “Top Health Breakthrough by a Female Scientist” (2005), the "Women in Science Award" from the American Medical Women’s Association and Wyeth Pharmaceutical Company for her contributions to autoimmune disease research (2006), and the Goldman Philanthropic Partnerships/Partnership for Cures “George and Judith Goldman Angel Award” for research to find an effective treatment for type 1 diabetes (2011). Her previous research accomplishments include the first scientific description of modifying donor tissue antigens to change their foreignness. This achievement earned her the prestigious National Institutes of Health and National Library of Medicine “Changing the Face of Medicine” Award (2003) as one of 300 American physicians (one of 35 in research) honored for seminal scientific achievements in the United States.
Dr. Faustman earned her MD and PhD from Washington University School of Medicine in St. Louis, Missouri, and completed her internship, residency, and fellowships in Internal Medicine and Endocrinology at the Massachusetts General Hospital in Boston, Massachusetts.
by G Ristori · 1999 · Cited by 89 · Related articles
Neurology. 1999 Oct 22;53(7):1588-9. Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis. Ristori G(1 ), Buzzi MG, Sabatini U, Giugni E, Bastianello S, Viselli F, Buttinelli C, Ruggieri S, Colonnese ...
Dec 6, 2013 · Giovanni Ristori, M.D., Ph.D., at Sapienza University, Rome, and his team administered the TB vaccine .... It could take years for BCG vaccine to become a standard treatment against MS ...
Official Title: Phase 2-3 Use of Bacille Calmette-Guèrin (BCG) Vaccine in Patients With a First Clinical Demyelinating Episode: a Multicenter, .... Buttinelli C, Salvetti M, Ristori G. Vaccinations and multiple ...
Coverage of Dr. Ristori and colleagues' trial using the BCG vaccine in multiple sclerosis: http://www.bbc.co. uk/news/health-25207033.
by G Ristori · 1999 · Cited by 89 · Related articles
Use of Bacille Calmette–Guèrin (BCG) in multiple sclerosis. G. Ristori, PhD,; M.G Buzzi, MD,; U. Sabatini, PhD,; E. Giugni, MD,; S. Bastianello, MD,; F. Viselli, MD,; C. Buttinelli, MD,; S. Ruggieri, MD ...
Jan 7, 2014 · Giovanni Ristori and his team at the Center for Neurological Therapies, University of Rome, Italy have shown that patients with CIS who were vaccinated with BCG had significantly reduced disease ...
Phase II BCG human clinical trial in type 1 diabetes, including the final regulatory approvals. .... Dr. Ristori's group is currently planning Phase. III trials in MS. Frequently Asked Questions. How can I register to ...
Dec 5, 2013 · Dr. Ristori added that there has been some experience with type 1 diabetes in which the BCG vaccine has been associated with an improvement in the course of the disease over long-term follow- up.
by M Kowalewicz-Kulbat · 2017 · Related articles
May 30, 2017 · Introduction: Bacillus Calmette-Guérin (BCG) is the only available vaccine against tuberculosis. Although its protective efficacy against pulmonary tuberculosis is still under debate, it provides ...
Denise Faustman · 2014 · Medical
Dr. Karaci's data shows that multiple doses of BCG, with the first dose in the neonatal period, are most ... Ristori, an expert on multiple sclerosis (MS), opened his talk with the historical point that the use of BCG or ...
No comments:
Post a Comment